iNtRON Biotechnology, Inc. (KOSDAQ:048530)
South Korea · Delayed Price · Currency is KRW 3,755.00
+90.00 (2.46%)
Feb 19, 2026, 3:10 PM KST
iNtRON Biotechnology Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -6,290 | -2,591 | -9,695 | 5,712 | 9,728 | 14,948 |
Depreciation & Amortization | 1,955 | 2,026 | 1,912 | 1,567 | 1,536 | 1,569 |
Loss (Gain) From Sale of Assets | 157.39 | -633.68 | -6.08 | 70.58 | 46.75 | -63.53 |
Loss (Gain) From Sale of Investments | 164.15 | 96.64 | 1,986 | 1,188 | -443.93 | -1,087 |
Loss (Gain) on Equity Investments | 227.65 | 186.27 | -228.32 | -172.72 | - | - |
Stock-Based Compensation | - | 17.6 | 377.77 | 360.17 | - | - |
Provision & Write-off of Bad Debts | -10.82 | -125.49 | -1,095 | 1,033 | 521.51 | 73.58 |
Other Operating Activities | 137.14 | -285.16 | 8,331 | -6,796 | 2,313 | 1,719 |
Change in Accounts Receivable | -13.74 | 1,211 | 2,937 | 5,163 | 1,643 | -9,239 |
Change in Inventory | 78.33 | -100.08 | -306.33 | 217.1 | 479.09 | -154.44 |
Change in Accounts Payable | -9.79 | 57.07 | -99.73 | -465.36 | 354.35 | -57.52 |
Change in Unearned Revenue | - | - | -1.17 | 4.89 | 48.49 | -35.97 |
Change in Other Net Operating Assets | -146.8 | 3.44 | -992.6 | -1,904 | 245.61 | -541.15 |
Operating Cash Flow | -3,751 | -138.47 | 3,118 | 5,977 | 16,473 | 7,131 |
Operating Cash Flow Growth | - | - | -47.84% | -63.72% | 131.00% | - |
Capital Expenditures | -2,209 | -1,122 | -7,791 | -2,229 | -3,046 | -4,852 |
Sale of Property, Plant & Equipment | - | 2,535 | 9 | - | 15 | - |
Sale (Purchase) of Intangibles | 80.14 | -64.49 | -257.73 | -388.01 | -297.69 | 30.16 |
Sale (Purchase) of Real Estate | - | 534 | -1,441 | - | -118.14 | -846.86 |
Investment in Securities | 1,031 | 1,058 | 61,273 | -43,676 | -38,082 | 8,003 |
Other Investing Activities | 55.98 | 87.01 | 357 | 80.66 | 130.44 | 91.73 |
Investing Cash Flow | -1,041 | 3,070 | 52,153 | -46,221 | -41,278 | 2,356 |
Long-Term Debt Issued | - | 861.44 | - | - | 40,000 | - |
Total Debt Issued | 3,861 | 861.44 | - | - | 40,000 | - |
Long-Term Debt Repaid | - | -174.62 | -40,168 | -196.82 | -250 | -2,010 |
Total Debt Repaid | -1,035 | -174.62 | -40,168 | -196.82 | -250 | -2,010 |
Net Debt Issued (Repaid) | 2,827 | 686.81 | -40,168 | -196.82 | 39,750 | -2,010 |
Repurchase of Common Stock | -5,932 | -7,186 | - | -8,994 | - | - |
Dividends Paid | -3,198 | -3,319 | - | - | - | - |
Other Financing Activities | 30 | - | - | -0.01 | -0.01 | -56.64 |
Financing Cash Flow | -6,273 | -9,818 | -40,168 | -9,191 | 39,750 | -2,066 |
Foreign Exchange Rate Adjustments | 128.8 | 258.96 | 72.75 | 76.59 | 298.74 | -907 |
Net Cash Flow | -10,937 | -6,628 | 15,175 | -49,359 | 15,243 | 6,514 |
Free Cash Flow | -5,960 | -1,260 | -4,673 | 3,748 | 13,427 | 2,279 |
Free Cash Flow Growth | - | - | - | -72.08% | 489.12% | - |
Free Cash Flow Margin | -107.24% | -19.64% | -48.75% | 26.76% | 45.81% | 5.02% |
Free Cash Flow Per Share | -187.00 | -38.30 | -140.80 | 110.49 | 398.07 | 64.59 |
Cash Interest Paid | 43.66 | - | 21.01 | 12.85 | 10.68 | 23.97 |
Cash Income Tax Paid | - | -405.72 | 293.4 | 1,184 | 229.22 | -134.45 |
Levered Free Cash Flow | -10,785 | -562.47 | -8,555 | 137.3 | 7,647 | -4,705 |
Unlevered Free Cash Flow | -10,743 | -547.84 | -6,731 | 2,328 | 8,669 | -3,965 |
Change in Working Capital | -92 | 1,171 | 1,537 | 3,016 | 2,771 | -10,028 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.